TITLE

Ticagrelor: The first approved reversible oral antiplatelet agent

AUTHOR(S)
Goel, Divya
PUB. DATE
January 2013
SOURCE
International Journal of Applied & Basic Medical Research;Jan2013, Vol. 3 Issue 1, p19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Platelet aggregation plays an important role in the pathophysiology of acute coronary syndrome (ACS). Aspirin is the most widely used antiplatelet agent and acts by inhibiting thromboxane A2-induced platelet activation. But it does not prevent platelets activation and aggregation by other signaling pathways like adenosine diphosphate (ADP) and Glycoprotein IIb/IIIa. Ticagrelor is the first oral reversible ADP (P2Y12) receptor antagonist. As compared to clopidogrel, ticagrelor has rapid onset as well as offset of action because of its reversible binding to P2Y12 receptor . It has potential to change the standard drug therapy of patient of ACS as shown in Platelet inhibition and patient outcomes (PLATO) trial, but long-term studies are required to further evaluate its efficacy and safety in these patients.
ACCESSION #
88046044

 

Related Articles

  • Secondary Prevention of Lacunar Stroke.  // Clinical Cardiology Alert;Nov2012 Clinical Briefs In Primary Care, p21 

    The article discusses the Secondary Prevention of Small Subcortical Strokes (SPS3) trial, which showed that Aspirin (ASA)+ clopidogrel (CLOP)was not as effective as ASA monotherapy in preventing lacunar strokes (L-CVA).

  • Secondary Prevention of Lacunar Stroke.  // Critical Care Alert;Nov2012 Clinical Briefs in Primary Care, p21 

    The article reports on the Secondary Prevention of Small Subcortical Strokes (SPS3) trial which finds that aspirin (ASA) along with clopidogrel (CLOP) is not more effective than ASA alone for prevention of lacunar stroke (L-CVA), and is also linked with greater bleeding risk and all-cause mortality.

  • Secondary Prevention of Lacunar Stroke. Kuritzky, Louis // Clinical Oncology Alert;Nov2012 Clinical Briefs In Primary Care, p21 

    The article discusses the Secondary Prevention of Small Subcortical Strokes (SPS3) trial, which showed that Aspirin (ASA)+ clopidogrel (CLOP)was not as effective as ASA monotherapy in preventing lacunar strokes (L-CVA).

  • Reducing Stroke Risk After TIA or Minor Ischemic Stroke. Kuritzky, Louis // Clinical Cardiology Alert;Sep2013 Clinical Briefs, p17 

    The article discusses the clinical trials conducted regarding the efficacy of dual antiplatelet therapy in reducing risk of stroke in patients who suffered transient ischemic attack (TIA) or minor ischemic stroke.

  • Optimal length of dual therapy is still unclear.  // BMJ: British Medical Journal;5/30/2015, Vol. 350 Issue 8010, p2841 

    The article discusses a study published in the journal "Annals of Internal Medicine" reveals the association between longer duration of dual antiplatelet therapy and fewer myocardial infarctions but more bleeding than treating for a shorter period.

  • New Clinical Advisory Issued by National Institute of Neurological Disorders and Stroke (NINDS).  // NLM Technical Bulletin;Sep2011, Issue 382, p11 

    The article offers information on the new clinical advisory by the National Institute of Neurological Disorders and Stroke (NINDS). It states that NINDS stopped the combination antiplatelet therapy for Secondary Prevention of Small Subcortical Strokes (SPS3) with randomized clinical trial in...

  • Triple Antiplatelet Therapy in Obese Patients Undergoing Stent Implantation. Balta, Sevket; Demirkol, Sait; Celik, Turgay; Unlu, Murat; Arslan, Zekeriya; Haqmal, Hamidullah // Angiology;Oct2013, Vol. 64 Issue 7, p559 

    A letter to the editor is presented in response to the article "Angiology efficacy and safety of triple antiplatelet" by W. Gao and colleagues in the January 27, 2013 issue.

  • Risks and benefits of antiplatelet therapies. Khan, Nazish // British Journal of Cardiac Nursing;May2015, Vol. 10 Issue 5, p236 

    This article will provide an overview of the key developments and advances seen within the field of antiplatelet therapies over the last decade. For each pharmacological agent currently used in clinical practice, the article will provide some insights into their mechanism of action along with...

  • Omeprazole and Clopidogrel -- Is There a Clinically Meaningful Interaction? Boyle, Andrew J. // Clinical Cardiology Alert;Jan2011, Vol. 30 Issue 1, p4 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics